FLOW trial: difference between revisions
Diff·revision 18 → 19·07:17, 7 Aug 2025
Difference between revision 18 and revision 19 of FLOW trial. 2 lines changed; the page grew by 169 bytes.
| Revision 18 — 17:37, 19 Jul 2025 CategoryBot (talk) bot: flag bare reference 4,414 bytes ±0 | Revision 19 — 07:17, 7 Aug 2025 CategoryBot (talk) bot: normalise trial registration identifier 4,583 bytes +169 | ||
|---|---|---|---|
| 38 | Together with [[SELECT trial|SELECT]] and [[LEADER trial|LEADER]]{{r|marso2016}} it forms the outcome evidence base for this molecule and its predecessor, and the pattern across those three — cardiovascular benefit in diabetes, cardiovascular benefit without diabetes, renal benefit in diabetic kidney disease — is what distinguishes an agent with outcome data from one with only intermediate endpoints.{{r|lincoff2023}} | 38 | Together with [[SELECT trial|SELECT]] and [[LEADER trial|LEADER]]{{r|marso2016}} it forms the outcome evidence base for this molecule and its predecessor, and the pattern across those three — cardiovascular benefit in diabetes, cardiovascular benefit without diabetes, renal benefit in diabetic kidney disease — is what distinguishes an agent with outcome data from one with only intermediate endpoints.{{r|lincoff2023}} |
| 39 | 39 | ||
| + | 40 | Whether the renal benefit is mediated by glycaemic control, weight, blood pressure, direct effects, or a combination is not established by the trial.{{r|perkovic2024}} | |
| + | 41 | ||
| 40 | == References == | 42 | == References == |
| 41 | {{reflist}} | 43 | {{reflist}} |